Tratamiento farmacológico y seguimiento de tumores neuroendocrinos gastroenteropancreaticos

  1. A. Sebastián-Ochoa 1
  2. C. Tenorio 2
  3. E. López-Mezquita Torres 3
  4. E. Torres Vela 1
  1. 1 S. Endocrinología y Nutrición. Hospital Virgen de la Victoria, Málaga
  2. 2 S. Endocrinología y Nutrición. H. Clínico San Cecilio, Granada.
  3. 3 S. Endocrinología y Nutrición. Fundación Jiménez- Díaz, Madrid
Mostrar afiliaciones +
Revista:
Cirugía Andaluza

ISSN: 2695-3811,  1130-3212

Año de publicación: 2009

Volumen: 20

Número: 1

Páginas: 25-30

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: Cirugía Andaluza

Referencias bibliográficas

  • Hamilon S, Aaltonen L. World Health Organization Classification of tumours. Pathology and genetics of the digestive system. Lyon: IARC Press, 2000
  • DeLlelis R, Lloyd RV, Heitz P, Eng C. World Health Organization Classification of tumours. Pathology and genetics of tumours of Endocrine organs. Lyon: IARC Press, 2004
  • Kaltsas GA, Besser GM, Grossmasn AB. The diagnosis and medical management of advanced neuroendocrine tumors. EndocrRev 2004; 25: 458-511
  • De Herder WW, Lamberts SW. Somatostatin and Somatostatin analogues: Diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14: 53-57
  • Dalm VA, Van Hagen PM, Van KoetsveldPM, Langerak AW, Van der Lely AJ, Lamberts SW et al. Cortistatin rather than somatostatin as a potencial endogenous ligang for somatostatin receptors in the human immune system. J. Clin Endocrinol Metab. 2003; 88:270-6
  • DelaunoitT, Rubin J, Neczyporenko F, Erlichman C; Hobday TJ. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005; 80:502-6.
  • Marazuela M, Bernabeu I. Tratamiento farmacológico de los tumours neuroendocrinos gastroenteropancreaticos : Análogos de somatostatina. Endocrinol Nutri. 2007; 54 (supl 1): 44-50
  • Oberg K, Kvols L, Caplin M, Delle Fave G, De Herder W, Rindi G et al. Consensus report of use of somatostatin analogs for the management of neuroendocrine tumours of the gastroenteropancreatic system. Ann Oncol. 2004; 15:966-73
  • Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Prac Res Clin Endocrinol Metab 2005; 19:213-27
  • Modlin I, Oberg K, Chung D, Jensen RT, De Herder W, Thakker R et al. Gastroenteropancreatic neuroendocrine tumours. Lancet 2008; 9: 61-72
  • Hofland LJ, Lambert SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistences. Endocr rev. 2003; 24: 28-47
  • Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE et al. Demostration of enhanced potency of a quimeric somatostatindopamine molecule, BIM – 23A387, in suppressing growth hormone and prolactin secretion frm human pituitary somatotroph adenoma cells. J. Clin Endocrinol Metab 2002; 87: 5545-52
  • Tomé M, Duran I, Salazar R, Díaz JA. Nuevos tratamientos en los tumores neuroendocrinos gastroenteropancreaticos. Endocrinol Nutr. 2007; 54 (supl 1): 51-7
  • Oberg K, Jelic S Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008; 19 supl 2: 104-5
  • ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors. Part 1 - Stomach, Duodenum and Pancreas. Neuroendocrinology 2006;84:155-215
  • ENETS Consensus Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumors. Part 2 - Midgut and Hindgut Tumors. Neuroendocrinology 2008;87(1):1-64
Fuente de los datos: Dialnet